Becker's Healthcare May 24, 2024
Mariah Taylor

FDA advisers have recommended the approval of Guardant Health’s blood test to detect colon or rectal cancers — but it also raised some concerns, NBC News reported May 23.

The panel voted 7-2 in favor of approving Gaurdant’s test, Shield. If the FDA does approve it, it will be the second blood-based test for colon cancer, competing with Epigenomics’ Epi proColon, which was approved in...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: FDA, Govt Agencies, Medical Devices, Patient / Consumer, Provider
FDA clears 1st cloud-based colonoscopy system
Rejecting a Psychedelic Drug for PTSD Treatment: Why and What’s Next
Advice for the FDA on regulating AI
Highly Anticipated FDA Decision Comes Just in Time for Back-to-School Season
COVID-19, flu and RSV shots—an epidemiologist explains why all three matter this fall

Share This Article